The association remained robust across sensitivity analysis, adjusting for the well-established cardiac biomarker NT-proBNP and a selected panel of key biomarkers of systemic inflammation (CRP, leukocytes, TNF, and IL-6), and in sensitivity analysis considering CAD as a competing event. This evidence concerns the gene NPPB and coronary artery disorder.